Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) EBT Margin (2022 - 2025)

Taysha Gene Therapies' EBT Margin history spans 4 years, with the latest figure at 1254.33% for Q2 2025.

  • For Q2 2025, EBT Margin rose 53398.0% year-over-year to 1254.33%; the TTM value through Sep 2025 reached 1492.06%, down 67103.0%, while the annual FY2024 figure was 1015.49%, 53743.0% down from the prior year.
  • EBT Margin for Q2 2025 was 1254.33% at Taysha Gene Therapies, down from 873.76% in the prior quarter.
  • Across five years, EBT Margin topped out at 7486.46% in Q1 2022 and bottomed at 1788.31% in Q2 2024.
  • The 4-year median for EBT Margin is 540.88% (2023), against an average of 597.86%.
  • The largest annual shift saw EBT Margin plummeted -786075bps in 2023 before it skyrocketed 53398bps in 2025.
  • A 4-year view of EBT Margin shows it stood at 4220.08% in 2022, then crashed by -110bps to 417.26% in 2023, then crashed by -116bps to 902.77% in 2024, then crashed by -39bps to 1254.33% in 2025.
  • Per Business Quant, the three most recent readings for TSHA's EBT Margin are 1254.33% (Q2 2025), 873.76% (Q1 2025), and 902.77% (Q4 2024).